{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupDescription":"The overall survival distributions of patients with Stage I-IV malignant rhabdoid tumors on AREN0321 and National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study (NCT00002610) were compared using the log-rank test.","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":".3478","paramType":"Log Rank Test Statistic","paramValue":".8814","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.1","upperLimit":"57.7","value":"38.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"The outcome of these patients will be compared with a fixed outcome based on that seen for similar patients treated with NWTS-5 regimen (NCT00002610).","dispersionType":"95% Confidence Interval","groups":[{"description":"Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphamide; x 30 weeks; XRT.","id":"OG000","title":"UH-1"}],"paramType":"NUMBER","populationDescription":"Eligible patients with Stage I-IV rhabdoid tumor.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors","type":"PRIMARY","unitOfMeasure":"Percentage of 4-year OS"}